Diamond Hill Capital Management LLC Investment Advisor Buys Shares of 475,941 Astrana Health, Inc. $ASTH

Diamond Hill Capital Management LLC Investment Advisor purchased a new position in Astrana Health, Inc. (NASDAQ:ASTH) in the second quarter, HoldingsChannel reports. The institutional investor purchased 475,941 shares of the company’s stock, valued at approximately $22,088,000.

Other institutional investors have also recently made changes to their positions in the company. Strs Ohio purchased a new stake in shares of Astrana Health during the 4th quarter valued at $40,000. Tower Research Capital LLC TRC grew its position in Astrana Health by 323.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock worth $115,000 after acquiring an additional 3,517 shares in the last quarter. State of Wyoming purchased a new position in Astrana Health in the second quarter worth $132,000. Los Angeles Capital Management LLC bought a new position in Astrana Health in the fourth quarter valued at $228,000. Finally, WINTON GROUP Ltd bought a new position in Astrana Health in the second quarter valued at $233,000. Institutional investors own 52.77% of the company’s stock.

Astrana Health Stock Performance

Astrana Health stock opened at $40.81 on Monday. The firm has a fifty day simple moving average of $41.34 and a two-hundred day simple moving average of $32.87. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 1.05. Astrana Health, Inc. has a twelve month low of $18.08 and a twelve month high of $51.60. The company has a market capitalization of $2.27 billion, a PE ratio of 49.77 and a beta of 0.87.

Analyst Ratings Changes

Several brokerages have issued reports on ASTH. Barclays lifted their price target on Astrana Health from $50.00 to $53.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Wall Street Zen lowered Astrana Health from a “buy” rating to a “hold” rating in a research report on Sunday. Robert W. Baird set a $45.00 price objective on Astrana Health in a report on Friday, May 8th. TD Cowen boosted their target price on Astrana Health from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Finally, BTIG Research upped their target price on Astrana Health from $50.00 to $65.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Astrana Health has a consensus rating of “Moderate Buy” and an average price target of $49.43.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.